SA519400792B1 - مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم - Google Patents

مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم

Info

Publication number
SA519400792B1
SA519400792B1 SA519400792A SA519400792A SA519400792B1 SA 519400792 B1 SA519400792 B1 SA 519400792B1 SA 519400792 A SA519400792 A SA 519400792A SA 519400792 A SA519400792 A SA 519400792A SA 519400792 B1 SA519400792 B1 SA 519400792B1
Authority
SA
Saudi Arabia
Prior art keywords
imidazo
pyridine derivatives
preparing
methods
same
Prior art date
Application number
SA519400792A
Other languages
English (en)
Inventor
جانج إونسونج
- هو بارك تشون
كيم جوزيف
كيم جيونجمين
تشون كوانجوو
لي هيونهو
بارك يونسون
Original Assignee
جيل فارماسوتيكال كو.، ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جيل فارماسوتيكال كو.، ليمتد. filed Critical جيل فارماسوتيكال كو.، ليمتد.
Publication of SA519400792B1 publication Critical patent/SA519400792B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات إيميدازو[1،2-a]بيريدين Imidazo[1,2-a]Pyridine Derivatives جديدة، وبشكل خاص بمشتقات إيميدازو[1،2-a]بيريدين لديها نشاط ممتاز لتثبيط إفراز الحمض المعدي inhibiting gastric acid secretion ، طرق لتحضيرهم، واستخدامهم. مشتقات الإيميدازو[1،2-a]بيريدين وفقًا للكشف الحالي لديها نشاط مثبط لإفراز الحمض المعدي، ومن ثم يُمكن استخدامه بشكل فعال في الوقاية أوعلاج أمراض التهابية بالمعدة والأمعاء gastrointestinal inflammatory diseases أو أمراض متعلقة بالحمض المعدي gastric acid-related diseases. شكل 1.
SA519400792A 2016-07-05 2019-01-02 مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم SA519400792B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160085048A KR101777971B1 (ko) 2016-07-05 2016-07-05 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
PCT/KR2017/007055 WO2018008929A1 (en) 2016-07-05 2017-07-04 Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof

Publications (1)

Publication Number Publication Date
SA519400792B1 true SA519400792B1 (ar) 2022-09-01

Family

ID=59926389

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519400792A SA519400792B1 (ar) 2016-07-05 2019-01-02 مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم

Country Status (22)

Country Link
US (1) US10696671B2 (ar)
EP (1) EP3481827B1 (ar)
JP (1) JP6713556B2 (ar)
KR (1) KR101777971B1 (ar)
CN (1) CN109415362B (ar)
AU (1) AU2017293271C1 (ar)
CA (1) CA3029745C (ar)
DK (1) DK3481827T3 (ar)
ES (1) ES2900305T3 (ar)
HU (1) HUE057549T2 (ar)
IL (1) IL264075B (ar)
MX (1) MX2018016299A (ar)
MY (1) MY196082A (ar)
NZ (1) NZ749346A (ar)
PH (1) PH12019500015A1 (ar)
PL (1) PL3481827T3 (ar)
PT (1) PT3481827T (ar)
RU (1) RU2725147C1 (ar)
SA (1) SA519400792B1 (ar)
SG (1) SG11201811221XA (ar)
WO (1) WO2018008929A1 (ar)
ZA (1) ZA201900236B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
KR20190057569A (ko) * 2017-11-20 2019-05-29 제일약품주식회사 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도
WO2020210878A1 (en) * 2019-04-18 2020-10-22 Borody Thomas J Compositions and methods for treating, ameliorating and preventing h. pylori infections
KR102496869B1 (ko) 2022-07-29 2023-02-07 제일약품주식회사 이미다조[1,2-a]피리딘 화합물의 신규 염, 이의 결정형 및 제조방법
WO2024117798A1 (ko) * 2022-11-29 2024-06-06 제일약품 주식회사 자스타프라잔 또는 이의 약제학적으로 허용되는 염을 포함하는 헬리코박터 파일로리 제균용 조성물
KR20240080172A (ko) 2022-11-29 2024-06-05 제일약품주식회사 자스타프라잔 또는 이의 약제학적으로 허용되는 염을 포함하는 헬리코박터 파일로리 제균용 조성물
WO2024117797A1 (ko) * 2022-11-29 2024-06-06 제일약품 주식회사 자스타프라잔 또는 이의 약제학적으로 허용되는 염을 포함하는 약제 연관 소화성 궤양의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81219B (en) * 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
PL1784404T3 (pl) 2004-09-03 2012-04-30 Yuhan Corp Pochodne pirolo[2,3-c]pirydyny i sposoby ich wytwarzania
US7498337B2 (en) 2005-08-30 2009-03-03 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2007039464A1 (en) * 2005-09-22 2007-04-12 Nycomed Gmbh Isotopically substituted imidazopyridine derivatives for the treatment of gastrointestinal disorders
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
WO2008015196A1 (en) 2006-07-31 2008-02-07 Nycomed Gmbh 5-,7-bis-substituted imidazo[1,2-a]pyridines
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
IL264075B (en) 2022-02-01
MX2018016299A (es) 2019-08-29
JP6713556B2 (ja) 2020-06-24
PH12019500015A1 (en) 2019-10-28
WO2018008929A1 (en) 2018-01-11
EP3481827B1 (en) 2021-11-03
IL264075A (en) 2019-01-31
CN109415362B (zh) 2021-07-30
EP3481827A1 (en) 2019-05-15
CA3029745A1 (en) 2018-01-11
PL3481827T3 (pl) 2022-02-07
CA3029745C (en) 2020-12-08
ES2900305T3 (es) 2022-03-16
NZ749346A (en) 2020-04-24
AU2017293271B2 (en) 2019-12-05
BR112018077205A2 (pt) 2019-04-09
US20190152971A1 (en) 2019-05-23
MY196082A (en) 2023-03-14
PT3481827T (pt) 2021-12-09
EP3481827A4 (en) 2019-11-27
HUE057549T2 (hu) 2022-05-28
ZA201900236B (en) 2020-05-27
AU2017293271C1 (en) 2020-04-23
DK3481827T3 (da) 2021-12-06
AU2017293271A1 (en) 2019-01-17
JP2019524691A (ja) 2019-09-05
US10696671B2 (en) 2020-06-30
SG11201811221XA (en) 2019-01-30
RU2725147C1 (ru) 2020-06-30
CN109415362A (zh) 2019-03-01
KR101777971B1 (ko) 2017-09-12

Similar Documents

Publication Publication Date Title
SA519400792B1 (ar) مشتقات إيميدازو [1،2-a] بيريدين، طرق لتحضيرهم واستخدامهم
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
ZA201904522B (en) Heterocyclic inhibitors of mct4
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
MX2017008416A (es) Formas solidas de un inhibidor de ask1.
PT3805233T (pt) Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
WO2015003816A3 (en) Cystobactamides
WO2017103670A8 (en) 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
TR201907590T4 (tr) Ssao inhibitörleri olarak imidazo[4,5-c]piridin ve pirrolo[2,3-c]piridin türevleri.
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2016022970A8 (en) Dihydropteridinone derivatives and uses thereof
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
SI3697784T1 (sl) Imidazo(4,5-B)piridinske spojine in farmacevtski sestavki iz teh za zdravljenje vnetnih motenj
MX2015015162A (es) Agente de reduccion de acido urico.
EP3675871A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF FIBROTIC DISEASES
TN2017000465A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
CU20180139A7 (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7- tetrahidro-3h-pirrolo[2,1-c][1,2,4]triazol-3-onas sustituidas y procedimientos de preparación